Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

BBBen BrikVPVineet Polineni

Discussion

Loading...

Member takes

Overview

Real-world analysis shows CAR-T therapy improves overall survival in DLBCL, suggesting a promising treatment option while noting higher toxicity risks.

Key Points

  • Overall survival improved for DLBCL patients receiving CAR-T compared to bispecific antibodies.
  • Cox proportional hazards analysis indicated CAR-T reduced the risk of progression to further treatment lines significantly.
  • Propensity score matching was applied to adjust for confounders in a national cohort analysis of DLBCL patients.
  • CAR-T was associated with greater hematotoxicity, indicating a need for careful patient monitoring post-treatment.

Cite This Study

Brik et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d512https://doi.org/10.1182/blood-2025-4532
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis2025
  2. 2Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations
  3. 3Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study2025
  4. 4Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy2025 · 1 citations
  5. 5Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2025